NasdaqGS:SRPTBiotechs
Sarepta’s First siRNA Move in Huntington’s Disease Could Be A Game Changer For Sarepta Therapeutics (SRPT)
Sarepta Therapeutics announced that Medsafe in New Zealand has approved its clinical trial application for INSIGHTT, a first-in-human Phase 1 study of SRP-1005, an investigational siRNA therapy for Huntington’s Disease, with the subcutaneous dose-escalation trial set to enroll around 24 participants.
This marks Sarepta’s move to clinically test an siRNA candidate in a condition with no approved disease-modifying treatments, potentially broadening its rare disease pipeline beyond existing...